Alnylam Pharmaceuticals Inc [ALNY] stock prices are up 2.44% to $401.8 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ALNY shares have gain 22.20% over the last week, with a monthly amount glided 21.84%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Truist started tracking the stock with Buy rating on July 21, 2025, and set its price target to $385. On March 31, 2025, Redburn Atlantic initiated with a Buy rating and assigned a price target of $353 on the stock. JP Morgan upgraded its rating to a Overweight and increased its price target to $328 on March 24, 2025. Wolfe Research downgraded its rating to a Underperform. In a note dated August 16, 2024, Goldman upgraded an Buy rating on this stock and boosted its target price from $198 to $370.
The stock price of Alnylam Pharmaceuticals Inc [ALNY] has been fluctuating between $205.87 and $402.43 over the past year. Currently, Wall Street analysts expect the stock to reach $363.25 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $401.8 at the most recent close of the market. An investor can expect a potential drop of -9.59% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
The Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] reported sales of 2.46B for trailing twelve months, representing a surge of 17.26%. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -2.74 and Total Capital is -0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of5.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 388.73 points at the first support level, and at 375.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 408.34, and for the 2nd resistance point, it is at 414.87.
Ratios To Look Out For
It’s worth pointing out that Alnylam Pharmaceuticals Inc [NASDAQ:ALNY]’s Current Ratio is 2.80. As well, the Quick Ratio is 2.75, while the Cash Ratio is 0.86. Considering the valuation of this stock, the price to sales ratio is 21.39, the price to book ratio is 210.01.
Transactions by insiders
Recent insider trading involved Greenstreet Yvonne, Chief Executive Officer, that happened on May 30 ’25 when 31640.0 shares were sold. Chief Executive Officer, Greenstreet Yvonne completed a deal on Jun 02 ’25 to sell 19297.0 shares. Meanwhile, Officer Greenstreet Yvonne bought 19297.0 shares on Jun 02 ’25.
